Market closedNon-fractionalADR
Cellectis/CLLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cellectis
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Ticker
CLLS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Paris, France
Employees
236
Website
www.cellectis.com
Cellectis Metrics
BasicAdvanced
$187M
Market cap
-
P/E ratio
-$2.21
EPS
3.08
Beta
-
Dividend rate
Price and volume
Market cap
$187M
Beta
3.08
52-week high
$3.77
52-week low
$0.96
Average daily volume
1
Financial strength
Current ratio
2.717
Long term debt to equity
59.709
Total debt to equity
66.902
Interest coverage (TTM)
-5.89%
Management effectiveness
Return on assets (TTM)
-32.81%
Return on equity (TTM)
-59.52%
Return on investment (TTM)
-40.55%
Valuation
Price to revenue (TTM)
7.356
Price to book
1.324
Price to tangible book (TTM)
1.659
Growth
Revenue change (TTM)
76.59%
Earnings per share change (TTM)
12.34%
3-year revenue growth (CAGR)
3.82%
What the Analysts think about Cellectis
Analyst Ratings
Majority rating from 9 analysts.
Cellectis Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 23
QoQ growth
Revenue
$3.5M
-81.68%
Net income
-$30M
-45.65%
Profit margin
-857.14%
196.59%
Cellectis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.58
-$0.19
-$0.31
-$0.70
-
Expected
-$0.48
-$0.45
-$0.42
-$0.22
-$0.29
Surprise
20.37%
-58.18%
-25.43%
223.51%
-
Cellectis News
AllArticlesVideos
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
GlobeNewsWire·1 day ago
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewsWire·4 weeks ago
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cellectis stock?
Cellectis (CLLS) has a market cap of $187M as of July 27, 2024.
What is the P/E ratio for Cellectis stock?
The price to earnings (P/E) ratio for Cellectis (CLLS) stock is 0 as of July 27, 2024.
Does Cellectis stock pay dividends?
No, Cellectis (CLLS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cellectis dividend payment date?
Cellectis (CLLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectis?
Cellectis (CLLS) has a beta rating of 3.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cellectis stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.